CompletedPhase 2NCT02307500

Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy

Studying Gonadal germ cell tumor

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Istituto Clinico Humanitas
Principal Investigator
Armando Santoro, MD
Istituto Clinico Humanitas
Intervention
Regorafenib(drug)
Enrollment
82 enrolled
Eligibility
18 years · All sexes
Timeline
2014 – 2020

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02307500 on ClinicalTrials.gov

Other trials for Gonadal germ cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Gonadal germ cell tumor →

← Back to all trials